Maja Cwalina

Maja Cwalina

Auto-generated profile, based on publicly available information

Maja Cwalina

Wroclaw Medical University

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
WWWeronika Wrona
Weronika Wrona
MDMałgorzata Dorożalska
Małgorzata Dorożalska
HLHanna Ludwisiak
Hanna Ludwisiak
WWWiktoria Wdowiak
Wiktoria Wdowiak
JOJulia Owsik
Julia Owsik
AWAnna Wojdas
Anna Wojdas
Background: Haemodialysis imposes substantial treatment burden, affecting medication adherence and health-related quality of life (HRQoL). This study assessed treatment burden and its associations with these outcomes in adults receiving haemodialysis. Aim: To assess treatment burden in adults with end-stage renal disease (ESRD) receiving haemodialysis and examine its associations with medication adherence and HRQoL. Materials and Methods: A systematic search of PubMed, Embase and Scopus was conducted for publications from 2000 to 2026. After deduplication of 290 records, manual screening yielded 37 eligible studies — restricted to systematic reviews, meta-analyses, clinical trials, and Mendelian randomisation analyses involving adults (≥18 years). Results: Treatment burden in haemodialysis patients is multidimensional, encompassing high pill burden, time demands and significant psychological distress. Non-adherence rates reached up to 50%, driven by regimen complexity, depression, and caregiver strain. Physical HRQoL was more severely impaired than mental HRQoL, with fatigue and musculoskeletal symptoms as primary drivers. Longer dialysis vintage correlated with progressive symptom worsening Conclusions: Treatment burden in ESRD patients undergoing haemodialysis significantly impairs medication adherence and HRQoL, particularly in physical domains. Integrated, patient-centred strategies, including regimen simplification and psychosocial support, are needed.

2 October 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
WWWeronika Wrona
Weronika Wrona
AWAnna Wojdas
Anna Wojdas
WWWiktoria Wdowiak
Wiktoria Wdowiak
MDMałgorzata Dorożalska
Małgorzata Dorożalska
MJMałgorzata Jurczyk
Małgorzata Jurczyk
WRWeronika Ryś
Weronika Ryś
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are primarily used in type 2 diabetes and obesity. Evidence suggests additional cardiovascular, renal, and neurological effects, with important socioeconomic implications. Aim: To evaluate GLP-1 RA effects beyond metabolic control, focusing on cardiovascular, renal, neurological, physical activity, and socioeconomic outcomes. Material and methods: PubMed, Embase, and Scopus were searched for studies published from 2022 to 2026. Adult human studies assessing cardiovascular, renal, cerebrovascular, neurological or socioeconomic outcomes were included. After screening, 39 publications were qualitatively synthesized. Results: GLP-1 RAs were associated with reduced major adverse cardiovascular events, cardiovascular mortality, myocardial infarction, and selected heart-failure outcomes. Semaglutide reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease. Neurological effects included reduced cerebrovascular events and intracranial pressure, while evidence regarding cognition and neurodegenerative disorders remained heterogeneous. Conclusions: GLP-1 RAs exert multisystem effects beyond metabolic control, including cardiovascular and renal protection and neurological effects. Their expanding use may provide substantial health benefits but also raises concerns regarding treatment costs and socioeconomic disparities in access.

2 October 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
MDMałgorzata Dorożalska
Małgorzata Dorożalska
MJMałgorzata Jurczyk
Małgorzata Jurczyk
AGAleksandra Glapa
Aleksandra Glapa
WWWeronika Wrona
Weronika Wrona
WWWiktoria Wdowiak
Wiktoria Wdowiak
WRWeronika Ryś
Weronika Ryś
Background. Prediabetes elevates lifetime risk of type 2 diabetes and cardiovascular disease. Moderate-intensity continuous training (MICT) improves metabolic health but is limited by time demands. High-intensity interval training (HIIT) is a time-efficient alternative that can match or exceed MICT benefits for insulin sensitivity and glycemic control, yet optimal protocols remain unclear. Aim. To evaluate the effects of HIIT on insulin sensitivity and metabolic health in adults with prediabetes. Material and methods. PubMed, Scopus and Google Scholar were searched for English-language peer-reviewed studies (2015–2026) on HIIT and insulin sensitivity or metabolic outcomes in adults with prediabetes. Eligible randomised controlled trials, controlled trials, observational studies and reviews were screened by title/abstract and full text after duplicate removal; reference lists were also hand-searched. Results. HIIT improved muscle and whole-body insulin sensitivity, reduced fasting glucose and HbA1c, and increased VO₂max, often comparably to MICT despite lower time commitment. Higher-volume protocols yielded greater HbA1c reductions; greater volume also strengthened benefits for fasting glucose, insulin and HOMA-IR. Combined HIIT plus diet produced the best BMI outcomes, while clamp-derived insulin sensitivity improvements partly depended on ≥3 % weight loss. Superiority over MICT varied by outcome and protocol. Conclusions. HIIT delivers meaningful gains in insulin sensitivity and metabolic health that are frequently comparable to MICT with substantially less time. Larger standardised trials are needed to define optimal, individualised prescriptions for type 2 diabetes prevention.

11 November 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
HLHanna Ludwisiak
Hanna Ludwisiak
MCMaja Cwalina
Maja Cwalina
JOJulia Owsik
Julia Owsik
WRWeronika Ryś
Weronika Ryś
MDMałgorzata Dorożalska
Małgorzata Dorożalska
AWAnna Wojdas
Anna Wojdas
Background: Chronic low back pain (CLBP) is a multifactorial condition influenced by physical, psychological, and social factors. Exercise therapy is a core element of conservative management, yet it encompasses highly heterogeneous interventions. Aim: This narrative review summarizes current evidence on the effectiveness and safety of exercise therapy for CLBP, focusing on exercise modalities, optimal doses, individualization, special populations, delivery methods, and practical implications. Material and Methods: A narrative literature review was conducted primarily through PubMed and completed in August 2026. The search was limited to studies published in the preceding five years involving adult participants with CLBP, including systematic reviews, meta-analyses, and randomized controlled trials. Results: Exercise therapy produces a clinically important reduction in pain intensity (approx. 15 points on a 0–100 scale) and a smaller improvement in functional disability compared to no treatment or placebo. No single exercise modality has demonstrated consistent superiority. Regular participation (15–30 minutes per session, three times per week, programs lasting at least 16 weeks) is favorable. Benefits are most evident versus inactive controls and diminish when compared with other active treatments. Adherence, individualization, and continued physical activity are key determinants of success. Exercise is generally safe, with mild, transient musculoskeletal symptoms being the most common adverse effects. Conclusions: Exercise therapy is an effective, adaptable, and safe non-pharmacological intervention for CLBP. Outcomes depend less on the specific modality than on adequate dosage, sustained adherence, and a patient-centred approach integrating individual preferences, functional goals, and psychological strategies.